Search results
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
Motley Fool via Yahoo Finance· 2 months agoSome investors might remember the obesity drugs developed by Arena Pharmaceuticals and Vivus...
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
Motley Fool· 1 year agoPfizer (NYSE: PFE) has been a company on a mission, looking to restock its pipeline with growth...
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
Motley Fool· 6 months agoPfizer's (NYSE: PFE) stock performance has been disappointing this year (down 38%). For example,...
2 Incredible Growth Stocks That Are Screaming Buys for 2024
Motley Fool via Yahoo Finance· 4 months agoThe new year is here, and for many, it's a fresh opportunity to set financial goals and find fresh...
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Q4 2022 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 year agoLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Q4 2022 Earnings Call Transcript March 2, 2023...
Is Pfizer Stock a Millionaire Maker?
Motley Fool via Yahoo Finance· 3 months agoThe stock market is at record levels these days, but one company that isn't reflecting that optimism is Pfizer (NYSE: PFE). Shares of the pharma giant...
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
Motley Fool· 1 year agoLast December, Pfizer (NYSE: PFE) essentially out-licensed its tumor necrosis factor-like ligand 1A...
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
Zacks via Yahoo Finance· 3 months agoPfizer PFE announced that the European Commission has granted marketing approval to its oral,...
2 Pharma Stocks for a Recession
Motley Fool· 2 years agoThe U.S. and countries worldwide have been experiencing a growing chorus of recession calls in 2022. Accordingly, the S&P 500 index is down 19% this...
US FDA approves Pfizer's inflammatory bowel disease drug
Reuters via Yahoo News· 8 months ago(Reuters) -The U.S. Food and Drug Administration has approved Pfizer's drug to treat adults with an...
